• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Oncology
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • AI Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Oncology
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • AI Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
eye with dollar sign
Pharma

Alcon acquires Neurotech and its approved Encelto for $550M

Alcon says it will now help take Encelto global and leverage Neurotech's technology to develop more convenient ocular therapies.
Donavyn Coffey Oct 21, 2026 10:56am
Podcast
The Next Chapter for AI in Clinical Trials

The Next Chapter for AI in Clinical Trials

Brought to you by Saama
 Pills medicine in Dollar sign shape on blue background

ICER, West Health call out excessive U.S. drug launch prices

Oct 21, 2026 10:36am
Why Are 53 of Phase 2 and 3 Trials Delayed A Redesign Is Overdue

Why Are 53% of Phase 2 and 3 Trials Delayed? A Redesign Is Overdue

Brought to you by Bain & Company
Waterhouse

CSL taps GSK’s Deborah Waterhouse as CEO in darkest hour

Oct 21, 2026 10:22am
GSK

GSK wins groundbreaking FDA green light in chronic hepatitis B

Oct 21, 2026 6:39am
More News

FDA finalizes guidance on prescription drug apps

Oct 20, 2026 5:59pm

Regulatory tracker: Viatris' Ryzumvi lands FDA presbyopia nod

Oct 20, 2026 3:00pm

Samsung Bio blunts impact of strike threat with court ruling

Oct 20, 2026 1:40pm

Antheia, DOD shake on $80M manufacturing loan

Oct 20, 2026 11:35am
Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings